311 related articles for article (PubMed ID: 34812550)
1. Aberrant RNA splicing and therapeutic opportunities in cancers.
Yamauchi H; Nishimura K; Yoshimi A
Cancer Sci; 2022 Feb; 113(2):373-381. PubMed ID: 34812550
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
3. [RNA splicing dysregulation in hematological malignancies].
Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
[TBL] [Abstract][Full Text] [Related]
4. Targeting splicing abnormalities in cancer.
Agrawal AA; Yu L; Smith PG; Buonamici S
Curr Opin Genet Dev; 2018 Feb; 48():67-74. PubMed ID: 29136527
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
7. H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.
Seiler M; Yoshimi A; Darman R; Chan B; Keaney G; Thomas M; Agrawal AA; Caleb B; Csibi A; Sean E; Fekkes P; Karr C; Klimek V; Lai G; Lee L; Kumar P; Lee SC; Liu X; Mackenzie C; Meeske C; Mizui Y; Padron E; Park E; Pazolli E; Peng S; Prajapati S; Taylor J; Teng T; Wang J; Warmuth M; Yao H; Yu L; Zhu P; Abdel-Wahab O; Smith PG; Buonamici S
Nat Med; 2018 May; 24(4):497-504. PubMed ID: 29457796
[TBL] [Abstract][Full Text] [Related]
8. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1.
Zhang J; Ali AM; Lieu YK; Liu Z; Gao J; Rabadan R; Raza A; Mukherjee S; Manley JL
Mol Cell; 2019 Oct; 76(1):82-95.e7. PubMed ID: 31474574
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
10. Splicing Factor Mutations in Cancer.
Bejar R
Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
12. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
Spinello A; Borišek J; Malcovati L; Magistrato A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
[TBL] [Abstract][Full Text] [Related]
13. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways: Understanding and Targeting Mutant Spliceosomal Proteins.
Yoshimi A; Abdel-Wahab O
Clin Cancer Res; 2017 Jan; 23(2):336-341. PubMed ID: 27836865
[TBL] [Abstract][Full Text] [Related]
15. RNA Splicing and Cancer.
Wang E; Aifantis I
Trends Cancer; 2020 Aug; 6(8):631-644. PubMed ID: 32434734
[TBL] [Abstract][Full Text] [Related]
16. Emerging roles of spliceosome in cancer and immunity.
Yang H; Beutler B; Zhang D
Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
[TBL] [Abstract][Full Text] [Related]
17. Overlapping roles of spliceosomal components SF3B1 and PHF5A in rice splicing regulation.
Butt H; Bazin J; Alshareef S; Eid A; Benhamed M; Reddy ASN; Crespi M; Mahfouz MM
Commun Biol; 2021 May; 4(1):529. PubMed ID: 33953336
[TBL] [Abstract][Full Text] [Related]
18. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping.
Wu G; Fan L; Edmonson MN; Shaw T; Boggs K; Easton J; Rusch MC; Webb TR; Zhang J; Potter PM
RNA; 2018 Aug; 24(8):1056-1066. PubMed ID: 29844105
[TBL] [Abstract][Full Text] [Related]
20. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
[Next] [New Search]
